Am­gen and No­var­tis back Aimovig with new da­ta as mi­graine com­pe­ti­tion heats up

Fac­ing a slew of com­peti­tors, Am­gen and No­var­tis are march­ing out new Phase IV re­sults to bol­ster Aimovig, their first-to-mar­ket CGRP in­hibitor for mi­graine pre­ven­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER